INR 103.77
(5.99%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.43 Billion INR | 13.17% |
2022 | 1.26 Billion INR | -6.52% |
2021 | 1.35 Billion INR | 20.94% |
2020 | 1.11 Billion INR | 112.49% |
2019 | 526.78 Million INR | -8.1% |
2018 | 573.2 Million INR | -21.77% |
2017 | 732.75 Million INR | -9.47% |
2016 | 809.42 Million INR | 33.48% |
2015 | 606.38 Million INR | -34.95% |
2014 | 932.22 Million INR | -25.71% |
2013 | 1.25 Billion INR | -9.17% |
2012 | 1.38 Billion INR | -78.97% |
2011 | 6.56 Billion INR | 408.41% |
2010 | 1.29 Billion INR | -80.41% |
2009 | 6.59 Billion INR | -3.63% |
2008 | 6.84 Billion INR | 13.2% |
2007 | 6.04 Billion INR | 20.82% |
2006 | 5 Billion INR | 44.64% |
2005 | 3.45 Billion INR | -0.85% |
2004 | 3.48 Billion INR | 1.03% |
2003 | 3.45 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -21.85 Billion INR | -1626.13% |
2023 Q1 | - INR | -100.0% |
2023 FY | 1.43 Billion INR | 13.17% |
2023 Q2 | 1.5 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q4 | 1.43 Billion INR | 0.0% |
2022 Q2 | 1.43 Billion INR | 0.0% |
2022 Q4 | 1.26 Billion INR | 0.0% |
2022 FY | 1.26 Billion INR | -6.52% |
2022 Q1 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2021 FY | 1.35 Billion INR | 20.94% |
2021 Q2 | 1.15 Billion INR | 0.0% |
2021 Q4 | 1.35 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2020 Q2 | 776.2 Million INR | 0.0% |
2020 Q4 | 1.11 Billion INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 FY | 1.11 Billion INR | 112.49% |
2020 Q3 | - INR | -100.0% |
2019 Q2 | 492.7 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 Q3 | - INR | -100.0% |
2019 Q4 | 526.78 Million INR | 0.0% |
2019 FY | 526.78 Million INR | -8.1% |
2018 FY | 573.2 Million INR | -21.77% |
2018 Q4 | 573.2 Million INR | 0.0% |
2017 FY | 732.75 Million INR | -9.47% |
2017 Q4 | 732.75 Million INR | 0.0% |
2016 Q4 | 809.5 Million INR | 0.0% |
2016 FY | 809.42 Million INR | 33.48% |
2015 Q3 | - INR | -100.0% |
2015 FY | 606.38 Million INR | -34.95% |
2015 Q4 | 606.38 Million INR | 0.0% |
2015 Q2 | 753.6 Million INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2014 Q3 | - INR | -100.0% |
2014 Q4 | 932.22 Million INR | 0.0% |
2014 FY | 932.22 Million INR | -25.71% |
2014 Q1 | - INR | -100.0% |
2014 Q2 | 1.14 Billion INR | 0.0% |
2013 Q2 | 1.52 Billion INR | 0.0% |
2013 Q4 | 1.25 Billion INR | 0.0% |
2013 FY | 1.25 Billion INR | -9.17% |
2013 Q1 | - INR | -100.0% |
2013 Q3 | - INR | -100.0% |
2012 FY | 1.38 Billion INR | -78.97% |
2012 Q2 | 1.61 Billion INR | 0.0% |
2012 Q3 | - INR | -100.0% |
2012 Q4 | 1.38 Billion INR | 0.0% |
2011 Q4 | 6.56 Billion INR | 0.0% |
2011 FY | 6.56 Billion INR | 408.41% |
2010 FY | 1.29 Billion INR | -80.41% |
2009 FY | 6.59 Billion INR | -3.63% |
2008 Q4 | 6.84 Billion INR | 0.0% |
2008 FY | 6.84 Billion INR | 13.2% |
2007 FY | 6.04 Billion INR | 20.82% |
2006 FY | 5 Billion INR | 44.64% |
2005 FY | 3.45 Billion INR | -0.85% |
2004 FY | 3.48 Billion INR | 1.03% |
2003 FY | 3.45 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Hester Biosciences Limited | 3.59 Billion INR | 60.161% |
RPG Life Sciences Limited | 1.38 Billion INR | -3.76% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 29.6% |
Ipca Laboratories Limited | 33.74 Billion INR | 95.756% |
Aarti Drugs Limited | 11.5 Billion INR | 87.551% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 82.643% |
Albert David Limited | 1.15 Billion INR | -24.519% |
Alkem Laboratories Limited | 48.6 Billion INR | 97.054% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 91.2% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -119.553% |
Bajaj HealthCare Limited | 4.86 Billion INR | 70.579% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -395.881% |
Brooks Laboratories Limited | 248.6 Million INR | -476.064% |
Eris Lifesciences Limited | 38.26 Billion INR | 96.258% |
FDC Limited | 3.7 Billion INR | 61.391% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 72.358% |
Gufic Biosciences Limited | 5.59 Billion INR | 74.426% |
Hikal Limited | 12.99 Billion INR | 88.98% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 37.448% |
Ind-Swift Limited | 13.45 Billion INR | 89.355% |
Innova Captab Limited | 4.89 Billion INR | 70.773% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 77.372% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -382.579% |
Jubilant Pharmova Limited | 61.27 Billion INR | 97.663% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -122.416% |
Laurus Labs Limited | 42.71 Billion INR | 96.647% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -33.275% |
Lupin Limited | 96.23 Billion INR | 98.512% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 27.537% |
Medico Remedies Limited | 438.24 Million INR | -226.781% |
Morepen Laboratories Limited | 4.45 Billion INR | 67.889% |
Nectar Lifesciences Limited | 11.21 Billion INR | 87.234% |
Orchid Pharma Limited | 3.84 Billion INR | 62.745% |
Procter & Gamble Health Limited | 2.56 Billion INR | 44.085% |
Sigachi Industries Limited | 2.53 Billion INR | 43.424% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 89.837% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.22% |
Themis Medicare Limited | 1.88 Billion INR | 24.128% |
Unichem Laboratories Limited | 8.06 Billion INR | 82.252% |
Vaishali Pharma Limited | 371.16 Million INR | -285.841% |
Venus Remedies Limited | 1.39 Billion INR | -2.822% |
Wanbury Limited | 3.15 Billion INR | 54.616% |
Windlas Biotech Limited | 1.76 Billion INR | 18.755% |
ZIM Laboratories Limited | 2.08 Billion INR | 31.174% |
Sakar Healthcare Limited | 1.26 Billion INR | -13.364% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.059% |
Divi's Laboratories Limited | 18.99 Billion INR | 92.459% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 60.883% |
Mankind Pharma Limited | 23.87 Billion INR | 94.002% |
Sequent Scientific Limited | 8.27 Billion INR | 82.692% |
Neuland Laboratories Limited | 5.49 Billion INR | 73.955% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 86.626% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.801% |
Zydus Lifesciences Limited | 71.79 Billion INR | 98.005% |
Amrutanjan Health Care Limited | 783.82 Million INR | -82.707% |
Wockhardt Limited | 39.87 Billion INR | 96.408% |
Bal Pharma Limited | 2.51 Billion INR | 42.973% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.661% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 32.091% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -796.233% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 59.148% |
Shilpa Medicare Limited | 12.93 Billion INR | 88.926% |
Valiant Laboratories Limited | 1.05 Billion INR | -35.326% |
Ajanta Pharma Limited | 10.71 Billion INR | 86.629% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 16.844% |
Granules India Limited | 22.95 Billion INR | 93.761% |
Medicamen Biotech Limited | 940.36 Million INR | -52.292% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -22.905% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.744% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.255% |
NATCO Pharma Limited | 10.53 Billion INR | 86.402% |
Suven Life Sciences Limited | 148.62 Million INR | -863.592% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 51.845% |
Strides Pharma Science Limited | 37.68 Billion INR | 96.199% |
Indoco Remedies Limited | 10.34 Billion INR | 86.153% |
Alpa Laboratories Limited | 307.12 Million INR | -366.297% |
Lasa Supergenerics Limited | 541.92 Million INR | -164.262% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 63.213% |